Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.58 |
| ▸ | EPAS1 | Q99814 | 11/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9219622 | 0.83 | HTR2C (0.54) | HIF1AEPAS1ALDH1A1HPGDKDM4E | |
| SCHEMBL3049240 | 0.81 | ALDH1A1 (0.46) | HIF1AEPAS1ALDH1A1HPGDKDM4E | |
| SCHEMBL9294695 | 0.80 | HIF1A (0.48) | HIF1AEPAS1 | |
| SCHEMBL30140565 | 0.79 | XDH (0.68) | HIF1AEPAS1ALDH1A1HPGDKDM4E | |
| SCHEMBL9475843 | 0.79 | ALDH1A1 (0.45) | HIF1AEPAS1ALDH1A1HPGDKDM4E | |
| SCHEMBL8723354 | 0.79 | XDH (0.68) | HIF1AEPAS1ALDH1A1HPGDKDM4E | |
| SCHEMBL2012004 | 0.79 | HIF1A (0.46) | HIF1AEPAS1ALDH1A1HPGDKDM4E | |
| SCHEMBL482227 | 0.79 | NPSR1 (0.49) | HIF1AEPAS1ALDH1A1HPGDKDM4E | |
| SCHEMBL6024450 | 0.79 | HTR2C (0.54) | HIF1AEPAS1ALDH1A1HPGDKDM4E | |
| SCHEMBL19600972 | 0.79 | HIF1A (0.41) | HIF1AEPAS1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| US-20160168161-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTIES, LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168161-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTIES, LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| WO-2010123139-A1 | ARYLCARBOXAMIDE DERIVATIVE HAVING SULFAMOYL GROUP | 持田製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
| US-6410678-B1 | HYDROXYL END GROUPS | TEIJIN LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1149852-A1 | AROMATIC POLYCARBONATE, PROCESS FOR PRODUCING THE SAME, AND MOLDED ARTICLE | TEIJIN LIMITED (JP) | 2001-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168161-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NAT10 | HIF1A 3098/4885EPAS1 4052/4885ALDH1A1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.